T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

This study is testing a new type of personalized cell therapy for advanced melanoma. Researchers remove tumor-fighting immune cells (tumor-infiltrating lymphocytes or TILs) from the patient's own tumor, use CRISPR gene editing to remove a checkpoint (PD-1) that normally suppresses those cells, then infuse the supercharged cells back into the patient. **You may be eligible if...** - You are between 18 and 75 years old - You have inoperable or metastatic melanoma (stage IIIc or IV) - Your cancer progressed after treatment with checkpoint inhibitor drugs (anti-PD-1 with or without anti-CTLA-4) - You have at least one tumor that can be surgically removed to make the TIL product - Your heart and organ function are adequate **You may NOT be eligible if...** - You have not yet tried standard immunotherapy - You have serious autoimmune disease, active infections, or poor organ function - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.